Umckaloabo: benefits, dosage, contraindications

Updated on

Native to the South African plateaus, Umckaloabo, scientifically known as Pelargonium sidoides, is a perennial herbaceous plant valued for its medicinal properties. Used for centuries in traditional Zulu medicine, it treats a variety of ailments, including respiratory infections, digestive disorders, and fatigue. Its name, Umckaloabo, comes from Zulu and means "severe cough" or "chest pain." This plant has thick roots, rich in compounds such as coumarins, tannins, and phenols: - Coumarins: including umckaline, known for its antimicrobial and immunomodulatory effects. - Hydrolyzable tannins: these compounds, such as gallic acid and ellagitannins, have astringent properties and help reduce inflammation. - Flavanols: like catechin and gallocatechin, which are powerful antioxidants that protect cells from damage caused by free radicals. These constituents are responsible for its multiple therapeutic effects, including antimicrobial, immunomodulatory, and anti-inflammatory actions. The root is primarily used for medicinal purposes, processed into standardized extracts to ensure clinical efficacy. Today, Umckaloabo is mainly recognized for its efficacy in treating acute respiratory infections such as bronchitis and colds.

Other name(s) 

a:0:{}

Scientific name(s)

Pelargonium sidoides

Family or group: 

Plants

Active ingredients:

Catechins

Gallic acid

Polyphenols


Indications

Rating methodology

EFSA approval.

Several clinical trials (> 2) randomized controlled with double blind, including a significant number of patients (>100) with consistently positive outcomes for the indication.
Several clinical trials (> 2) randomized controlled with double blind, and including a significant number of patients (>100) with positive outcomes for the indication.
One or more randomized studies or multiple cohorts or epidemiological studies with positive outcomes for the indication.
Clinical studies exist but are uncontrolled, with conclusions that may be positive or contradictory.
Lack of clinical studies to date that can demonstrate the indication.


Bronchitis
✪✪✪✪

Clinical studies and meta-analyses show that Pelargonium sidoides, administered within 48 hours of symptom onset, significantly reduces cough intensity and promotes faster symptom recovery after 7 days of treatment compared to placebo. The product used, EPs 7630, is administered in liquid form (30 drops three times a day) or in tablets (10-30 mg three times a day). In children, an adjusted dosage (10-20 drops three times a day) also reduces fever and medication needs.

Posologie

posologieOral: root

posologie30 mg

formulationstandardized extract


Cold, Respiratory infections
✪✪✪✪

Pelargonium sidoides extracts (EPs 7630) prove effective in reducing the severity and duration of common cold symptoms, notably cough and nasal congestion. A meta-analysis of five studies shows a decrease in subjective symptom intensity scores, reduction in the number of sick leave days, and improved sleep quality. Doses range from 1.5 mL to 3 mL three times a day for 5 to 10 days. Analyses also indicate comparable efficacy against human coronavirus infections (excluding COVID-19). These results position Pelargonium sidoides among the most promising plants against common respiratory infections.

Posologie

posologieOral: root

posologie30 mg

formulationstandardized extract


Properties


Antimicrobial

full-leaffull-leaffull-leafempty-leaf

The antimicrobial effect of Pelargonium sidoides is mainly attributed to its coumarins (particularly umckaline), tannins, and proanthocyanidins. These compounds inhibit the growth of many pathogenic bacteria by altering their cell membrane permeability, disrupting essential functions. Tannins, with their astringent properties, precipitate bacterial proteins, reducing their adherence to mucous membranes. Root extracts of Pelargonium sidoides, notably in acetone or standardized product form (EPs 7630), show antibacterial activity in vitro against various pathogens, including Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, and multi-resistant strains of Staphylococcus aureus. They also act against Hemophilus influenzae. Additionally, the root extract shows in vitro activity against Mycobacterium tuberculosis and other mycobacteria. However, antibacterial activity remains lower than that of conventional antibiotics like penicillin or erythromycin.

Usages associés

Cold

Immunomodulator

full-leaffull-leafempty-leafempty-leaf

Pelargonium sidoides stimulates the innate and adaptive immune response. Root extracts enhance macrophage phagocytosis and activate dendritic cells, essential for antigen presentation. They also induce the release of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), promoting a rapid response against infections. This dual modulation and stimulation effect allows the plant to strengthen natural defenses without triggering an excessive reaction.

Usages associés

Bronchitis

Antiviral

full-leaffull-leafempty-leafempty-leaf

The antiviral properties of Pelargonium sidoides are attributed to its polyphenols, which directly inhibit viral replication. These compounds act by blocking the attachment of viruses to host cells, thus preventing their penetration and spread. Additionally, tannins strengthen the mucosal barrier, limiting virus invasion. These combined actions are particularly effective against viruses responsible for acute respiratory infections, such as rhinoviruses or influenza viruses.

Usages associés

Cold


Safety dosage

Adult: 30 mg - 1200 mg (standardized extract)

The tablet form is most often used at a dose of 10-40 mg three times a day for 7-10 days.

Child: 3 mL (fluid extract)

A specific extract of Pelargonium sidoides (EPs 7630, Dr. Willmar Schwabe Pharmaceuticals) at a dose of 3 ml per day was used in children aged 6 to 10 years for a period of up to 7 days.


Precautions

Pregnant woman: avoid

Insufficient data.

Lactating woman: avoid

Insufficient data.